1-((6-Chloropyridin-3-yl)methyl)-4-ethylpiperazine

Catalog No. :
ACMYQO812
CAS No. :
1016745-43-9
Molecular Formula :
C12H18ClN3
Molecular Weight :
239.75

IUPAC Name:1-((6-chloropyridin-3-yl)methyl)-4-ethylpiperazine

1-((6-Chloropyridin-3-yl)methyl)-4-ethylpiperazine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$137.00Login to see priceIn stockInquiry
250mg95%$228.00Login to see priceIn stockInquiry
1g95%$429.00Login to see priceIn stockInquiry
5g95%$1664.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-((6-Chloropyridin-3-yl)methyl)-4-ethylpiperazine
IUPAC Name1-((6-chloropyridin-3-yl)methyl)-4-ethylpiperazine
MDL No.MFCD09804878
Molecular FormulaC12H18ClN3
Molecular Weight239.75
SMILESCCN1CCN(CC2=CC=C(Cl)N=C2)CC1
InChI KeyKKMXNCSANLDBQL-UHFFFAOYSA-N
Synonym1-[(6-chloropyridin-3-yl)methyl]-4-ethylpiperazine;Piperazine, 1-[(6-chloro-3-pyridinyl)methyl]-4-ethyl-;1-(6-Chloro-3-pyridinyl)methyl-4-ethyl-piperazine;Abemaciclib Impurity 48
CAS No.1016745-43-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACMYQO812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLREB347 route compound structure diagram
    ACLREB347124425-84-9 In Stock
  2. Then
  3. ACMYQO812 route product structure diagram
    ACMYQO8121016745-43-9 In Stock
Inquiry

2. ACMYQO812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACCTJM471 route compound structure diagram
    ACCTJM47123100-12-1 In Stock
  4. Then
  5. ACMYQO812 route product structure diagram
    ACMYQO8121016745-43-9 In Stock
Inquiry

Comments (0)